Logo

Teva and Alvotech Collaborate to Commercialize Five Biosimilar Candidates in the US

Share this
Teva and Alvotech Collaborate to Commercialize Five Biosimilar Candidates in the US

Teva and Alvotech Collaborate to Commercialize Five Biosimilar Candidates in the US

Shots:

  • Alvotech will lead the development- registration- and supply of the biosimilars- while Teva will be exclusively commercializing the products in the US. Alvotech will receive upfront with subsequent milestone payments over the next several years
  • The companies will share the profit from the commercialization of the biosimilars. The collaboration leverages Teva’s commercial presence and extensive infrastructure in the US along with Alvotech’s experience and state-of-the-art biologics manufacturing
  • The collaboration will improve patient access for high-quality biosimilar medicines in the US

­ Ref: Teva | Image: PharmaShots

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions